Anti-Mouse CXCL9 (Clone MIG-2F5-5) – Purified in vivo GOLD™ Functional Grade

Clone MIG-2F5-5 is a monoclonal antibody widely used in in vivo mouse studies to neutralize mouse CXCL9 (also known as MIG, Monokine Induced by Gamma interferon), a chemokine crucial for immune cell recruitment during inflammation and immune responses.

In vivo, MIG-2F5-5 is administered to mice to block or neutralize endogenous CXCL9 activity, thereby allowing researchers to study the physiological and pathological roles of CXCL9. Here are key points about its usage:

• Primary application: In vivo neutralization of murine CXCL9, typically to investigate CXCL9's role in immune cell trafficking (such as T cells and NK cells) in disease models, including infection, tumor microenvironment, autoimmunity, and inflammation.
• Antibody characteristics: It is an Armenian hamster IgG antibody, rigorously purified, with low endotoxin content suitable for safe in vivo use.
• Administration: The antibody is injected into mice, where it binds to and blocks CXCL9 protein, thus inhibiting its interaction with the CXCR3 receptor on leukocytes. This can modulate immune responses and help determine the specific contribution of CXCL9 in various biological processes or disease states.
• Reported applications: Besides in vivo neutralization, clone MIG-2F5-5 is also used in immunofluorescence for tissue localization studies.
• Controls and formulation: The product is delivered unconjugated and formulated in PBS without preservatives, and users are advised to use appropriate isotype controls for experimental rigor.

Research involving this antibody has clarified CXCL9's contribution to T cell recruitment, tumor immune infiltration, and inflammatory responses. The antibody's specificity for mouse CXCL9 is validated by ELISA and other methods.

When planning in vivo experiments, typical protocols involve antibody injection (intraperitoneal or intravenous) at doses and schedules optimized for the specific study objective and disease model.

In summary, clone MIG-2F5-5 is a validated reagent for functional inhibition of mouse CXCL9 in live animal studies, primarily to dissect the chemokine's role in immune cell trafficking and its broader immunological effects.

The correct storage temperature for the sterile packaged clone MIG-2F5-5 (anti-Mouse CXCL9) is 2–8°C (refrigerator temperature) for up to one month. For longer-term storage, it is recommended to aseptically aliquot the antibody in working volumes (without diluting) and store at -70°C (ultra-low freezer). Avoid repeated freeze-thaw cycles to maintain antibody integrity.

Based on the available information, there are limited specific details about commonly co-used antibodies or proteins with MIG-2F5-5 in the literature. However, the search results do provide some insights into related molecules and experimental contexts.

Related Antibodies and Proteins

The search results mention a few specific antibodies that have been used in research contexts involving CXCL9 and the MIG-2F5-5 antibody:

Anti-TIM-3 antibodies are mentioned as being used in conjunction with CXCL9 research, where anti-TIM-3 treatment enhances CXCL9 expression in CD8?+ cDC1 dendritic cells.

Anti-Galectin-9 neutralizing antibodies have been used in studies examining CXCL9 expression, with these antibodies leading to increased CXCL9 expression comparable to anti-TIM-3 antibody effects.

CXCL9 Pathway Components

Since MIG-2F5-5 targets CXCL9, research involving this antibody likely intersects with other components of the CXCL9 signaling pathway:

CXCR3 receptor is the primary receptor for CXCL9, and antibodies or reagents targeting CXCR3 would be relevant in functional studies.

Related chemokines including CXCL10 and CXCL11 are frequently studied alongside CXCL9, as they share the CXCR3 receptor and have overlapping functions in immune cell migration and activation.

Cellular Context Markers

Given that CXCL9 is expressed by various cell types, researchers using MIG-2F5-5 likely employ cell-type-specific markers:

• Macrophage and monocyte markers since these cells are major CXCL9 producers
• Endothelial cell markers for studying CXCL9 expression in vascular contexts
• Dendritic cell markers particularly for CD8?+ cDC1 cells where CXCL9 expression is regulated
• Cancer cell markers since CXCL9 is secreted by tumor cells in response to IFN-?

The search results indicate that MIG-2F5-5 has applications in flow cytometry, immunofluorescence, and neutralization studies, suggesting it's commonly used alongside fluorescent markers and other detection antibodies in these experimental contexts.

Clone MIG-2F5-5 (also referenced as MIG-2F5.5) is a monoclonal antibody that specifically targets mouse CXCL9 (also known as MIG, Monokine Induced by Gamma Interferon), and is widely cited in studies investigating immune cell dynamics, T cell recruitment, and tumor immune microenvironments.

Key findings from scientific literature citing clone MIG-2F5-5:

• Neutralization of CXCL9 impacts immune cell recruitment:

  • Use of anti-CXCL9 (MIG-2F5.5) in vivo antibodies effectively neutralizes murine CXCL9 and has been employed to analyze the role of CXCL9 in recruiting CD4+ and CD8+ T cells, and NK cells through its interaction with the CXCR3 receptor.
  • Neutralizing CXCL9 decreases infiltration of CD4+ and CD8+ T cells in tumor models, demonstrating its critical role in T cell migration to tumor sites, which directly affects tumor growth and immune response.

• Role in tumor immunology and metastasis:

  • Studies show that when IFN?2 delivered via lipid nanoparticles induces CXCL9 expression, blocking CXCL9 with MIG-2F5.5 significantly inhibits T cell accumulation and consequently impairs anti-tumor immunity. This effect leads to larger primary tumors and increased lung metastasis, highlighting CXCL9’s importance in mediating IFN-induced immune protection against tumors.

• Acute allograft rejection and immune modulation:

  • Co-administration of MIG-2F5.5 with anti-CXCR3 antibodies can limit acute allograft rejection more effectively than CXCL9 blockade alone, suggesting CXCL9 is a key player in regulating alloreactive cytotoxic T lymphocyte and regulatory T cell dynamics in transplantation models.

• Reported applications:

  • MIG-2F5-5 is cited for applications in in vivo neutralization of CXCL9 and immunofluorescence for flow cytometry, allowing researchers to track CXCL9’s role across diverse cell types, including monocytes, macrophages, endothelial cells, dendritic cells, fibroblasts, and cancer cells.

Summary table:

Additional context:

• CXCL9 is secreted in response to IFN-? and its expression is associated with various cells involved in immune responses, particularly within inflamed or tumorous tissues.
• Antibody MIG-2F5-5 is Armenian Hamster IgG specific for mouse CXCL9, and is used to dissect CXCL9-dependent immune mechanisms in preclinical models.

If you require specific publication summaries or direct study outcomes, please clarify the context or desired research focus.